R&D Division, Daiichi Sankyo Co., Ltd, 1-2-58 Hiromachi, Tokyo 140-8710, Japan.
Bioorg Med Chem Lett. 2013 Jun 1;23(11):3325-8. doi: 10.1016/j.bmcl.2013.03.104. Epub 2013 Apr 4.
2-Phenyl-4-piperidinyl-6,7-dihydrothieno[3,4-d]pyrimidine derivative (2) was found to be a new PDE4 inhibitor with moderate PDE4B activity (IC50=150 nM). A number of derivatives with a variety of 4-amino substituents and fused bicyclic pyrimidines were synthesized. Among these, 5,5-dioxo-7,8-dihydro-6H-thiopyrano[3,2-d]pyrimidine derivative (18) showed potent PDE4B inhibitory activity (IC50=25 nM). Finally, N-propylacetamide derivative (31b) was determined as a potent inhibitor for both PDE4B (IC50=7.5 nM) and TNF-α production in mouse splenocytes (IC50=9.8 nM) and showed good in vivo anti-inflammatory activity in the LPS-induced lung inflammation model in mice (ID50=18 mg/kg). The binding mode of the new inhibitor (31e) in the catalytic site of PDE4B is presented based on an X-ray crystal structure of the ligand-enzyme complex.
2-苯基-4-哌啶基-6,7-二氢噻吩并[3,4-d]嘧啶衍生物(2)被发现是一种具有中等 PDE4B 活性(IC50=150 nM)的新型 PDE4 抑制剂。合成了许多具有各种 4-氨基取代基和稠合双环嘧啶的衍生物。其中,5,5-二氧代-7,8-二氢-6H-噻吩并[3,2-d]嘧啶衍生物(18)表现出很强的 PDE4B 抑制活性(IC50=25 nM)。最后,N-丙基乙酰胺衍生物(31b)被确定为 PDE4B 的强抑制剂(IC50=7.5 nM)和 TNF-α在小鼠脾细胞中的产生(IC50=9.8 nM),并在 LPS 诱导的小鼠肺炎症模型中表现出良好的体内抗炎活性(ID50=18 mg/kg)。根据配体-酶复合物的 X 射线晶体结构,提出了新型抑制剂(31e)在 PDE4B 催化位点的结合模式。